Want to see GB:GENF full AI Analyst Report?
GENF Stock Chart & Stats
2.05 p
0.00 p(0.00%)
At close: 4:00 PM EDT
2.05 p
0.00 p(0.00%)
Day’s Range― - ―
52-Week Range1.21 p - 3.12 p
Previous CloseN/A
Volume3.08M
Average Volume (3M)3.81M
Market Cap
£10.40M
Enterprise Value11.17M
Total Cash (Recent Filing)£632.55K
Total Debt (Recent Filing)£0.00
Price to Earnings (P/E)―
Beta-0.21
Next Earnings
Apr 28, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding594,534,800
10 Day Avg. Volume3,275,768
30 Day Avg. Volume3,806,993
Financial Highlights & Ratios
PEG Ratio0.19
Price to Book (P/B)-14.33
Price to Sales (P/S)0.00
P/FCF Ratio-5.50
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Debt-Free Balance SheetThe absence of debt reduces interest obligations and refinancing exposure, giving the company more flexibility than a similarly loss-making biotech with leverage. This supports continued investment in research while limiting the direct financial burden during development.
Positive Gross ProfitPositive gross profit indicates that current revenue exceeds direct costs, providing an underlying contribution before operating expenses. Although insufficient to cover the broader cost base today, this offers a foundation for improved economics if revenue scales.
Returning Positive EquityThe return to positive TTM equity provides some balance-sheet support and indicates that the company is not currently showing negative net assets on that measure. This is a constructive position for funding research and maintaining operations.
Bears Say
Declining RevenueDeclining revenue indicates weakening commercial traction and reduces the resources available to fund research internally. For an early-stage biotechnology company, sustained top-line contraction can delay development progress and increase dependence on future financing.
Deep Operating LossesLarge losses relative to revenue show that the current operating base remains far ahead of commercial scale. Unless revenue expands or expenses are reduced, persistent losses will continue consuming equity and constrain the company’s ability to advance programs.
Persistent Cash BurnOngoing negative operating and free cash flow means the business is consuming cash rather than funding itself. Continued burn can reduce financial flexibility and create recurring financing needs, particularly while revenue remains modest and declining.
Genflow Biosciences Plc News
GENF FAQ
What was Genflow Biosciences Plc’s price range in the past 12 months?
Genflow Biosciences Plc lowest share price was 1.21 p and its highest was 3.12 p in the past 12 months.
What is Genflow Biosciences Plc’s market cap?
Genflow Biosciences Plc’s market cap is £10.40M.
When is Genflow Biosciences Plc’s upcoming earnings report date?
Genflow Biosciences Plc’s upcoming earnings report date is Apr 28, 2027 which is in 190 days.
How were Genflow Biosciences Plc’s earnings last quarter?
Genflow Biosciences Plc released its earnings results on Sep 29, 2026. The company reported -0.001 p earnings per share for the quarter.
Is Genflow Biosciences Plc overvalued?
According to Wall Street analysts Genflow Biosciences Plc’s price is currently Overvalued.
Does Genflow Biosciences Plc pay dividends?
Genflow Biosciences Plc does not currently pay dividends.
What is Genflow Biosciences Plc’s EPS estimate?
Genflow Biosciences Plc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Genflow Biosciences Plc have?
Genflow Biosciences Plc has 594,534,800 shares outstanding.
What happened to Genflow Biosciences Plc’s price movement after its last earnings report?
Genflow Biosciences Plc reported an EPS of -0.001 p in its last earnings report. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Genflow Biosciences Plc?
Currently, no hedge funds are holding shares in GB:GENF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Genflow Biosciences Plc
Genflow Biosciences plc, together with its subsidiaries, engages in the research and development of gene therapy targeting the upstream biology of aging in the United Kingdom and Belgium. The company operates as a pre-clinical biotechnology company that focuses on developing biological interventions aimed at tackling the effects of aging, slowing, and halting the aging process, as well as reducing the incidence of age-related diseases. Its lead drug candidate is GF-1002, a suspension of an adeno-associated viral vector-based gene therapy for intravenous infusion. The company is also developing GF-1003, a topical delivery of SIRT6 to the fibroblasts in the skin; GF-1004, a non-human pipeline anti-aging for veterinary use; GF-1005, which addresses mitochondrial dysfunction observed in sarcopenia for muscle health and combat sarcopenia; and GF-1006, an ophthalmology mRNA cent SIRT6 for the treatment of cornea pathologies and glaucoma. The company has collaborative research agreements with Revatis SA and EXO Biologics for therapy medicinal products. Genflow Biosciences plc was founded in 2020 and is headquartered in London, the United Kingdom.
Technical Analysis
Oxford BioDynamics
―
Physiomics
―
Fusion Antibodies Plc
―
4basebio UK Societas
―
Aptamer Group Plc
―